Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects
Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long-term phase II clinical trials.
Authors
- Sooyoun Lee
- Hyun Chul Kim (ORCID: https://orcid.org/0000-0002-8819-4780)
- Sang‐Ku Yoo (ORCID: https://orcid.org/0000-0002-2090-4256)
- Young‐Ran Yoon (ORCID: https://orcid.org/0000-0003-2166-7579)
- In‐Jin Jang (ORCID: https://orcid.org/0000-0002-8384-3139)
- Kyung‐Sang Yu (ORCID: https://orcid.org/0000-0003-0921-7225)
Institutions
- Kyungpook National University Hospital (KR)
- Seoul National University Hospital (KR)
- Kyungpook National University (KR)
- Glaceum (South Korea) (KR)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1002/bcp.70311
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kyungpook National University
- Kyungpook National University Hospital